𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group

✍ Scribed by David Osoba; Benny Zee


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
143 KB
Volume
17
Category
Article
ISSN
0277-6715

No coin nor oath required. For personal study only.

✦ Synopsis


The approach of the National Cancer Institute of Canada Clinical Trials Group to measuring compliance, that is, completion rates, for health-related quality of life questionnaires is presented. Completion rates can be measured at the institutional, patient, questionnaire and item levels for baseline, on-treatment and off-treatment follow-up study periods. Time windows are defined for each expected completion time. In seven completed clinical trials, completion rates were high with more than 93 per cent of patients completing questionnaires in the specified time windows at baseline and while on-treatment. The rate while on off-treatment follow-up is still acceptable at 85 per cent. The proportions of analysable questionnaires were 97)6 per cent, 82)0 per cent and 77)0 per cent respectively, at the three study periods. Item completion rates within questionnaires were high at 95)5 per cent or more. The variables most likely to influence baseline and on-treatment questionnaire completion rates were breast cancer, ovarian cancer, metastases and study centre size.


πŸ“œ SIMILAR VOLUMES


Practical issues in quality of life asse
✍ JΓΌrg Bernhard; Heidi Gusset; Christoph HΓΌrny πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 130 KB πŸ‘ 2 views

Quality of life (QOL) assessment has become an integrated part in some advanced disease trials and to a lesser extent in early disease trials conducted by the Swiss Group for Clinical Cancer Research (SAKK). In general, the concept of QOL endpoints and the additional work of collecting these data is

Phase II study of pemetrexed disodium, a
✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 1 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati